VIENNA — The highly selective oral Janus kinase (JAK) inhibitor SHR0302 (ivarmacitinib) enables more patients with active rheumatoid arthritis to meet American College of Rheumatology (ACR) response ...
Clinical Trials Arena on MSN
Lynk’s selective JAK inhibitor claims Phase III RA win
Lynk’s zemprocitinib commercial partner, Simcere, will now continue the JAK inhibitor’s development across China in RA.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results